首页> 外国专利> Use of a selective inhibitor of noradrenaline reuptake combined with phenylalanine or tyrosine to treat various diseases

Use of a selective inhibitor of noradrenaline reuptake combined with phenylalanine or tyrosine to treat various diseases

机译:使用去甲肾上腺素再摄取选择性抑制剂联合苯丙氨酸或酪氨酸治疗各种疾病

摘要

A method of treatment of disorders of neurological origin and drug formulations for use in the method are disclosed. These conditions comprise fatigue and associated syndromes of pain, weakness and depressed mood which are associated with chronic fatigue syndrome, brain injury and stroke, stress, fibromyalgia, and irritable bowel syndrome. The treatment comprises administering to a patient in need thereof a selective inhibitor of noradrenaline reuptake combined with either phenylalanine or tyrosine in the same dosage form or the same pack. The noradrenergic drug may be selected from lofepramine, desipramine or reboxetine. The selective inhibitor may be a combined inhibitor of both noradrenaline and serotonin reuptake such as venlafaxine, duloxetine or milnacipran, or an inhibitor of both noradrenaline and dopamine reuptake such as bupropion.
机译:公开了一种治疗神经系统疾病的方法和用于该方法的药物制剂。这些状况包括疲劳和与疼痛,虚弱和情绪低落有关的综合症,与慢性疲劳综合症,脑损伤和中风,压力,纤维肌痛和肠易激综合症有关。该治疗包括以相同剂型或相同包装向有需要的患者施用去甲肾上腺素再摄取的选择性抑制剂与苯丙氨酸或酪氨酸组合。去甲肾上腺素能药物可以选自洛非拉明,地昔帕明或瑞波西汀。选择性抑制剂可以是去甲肾上腺素和5-羟色胺再摄取的联合抑制剂,例如文拉法辛,度洛西汀或米那普仑,或者是去甲肾上腺素和多巴胺再摄取的抑制剂,例如安非他酮。

著录项

  • 公开/公告号NZ518306A

    专利类型

  • 公开/公告日2004-04-30

    原文格式PDF

  • 申请/专利权人 LAXDALE LIMITED;

    申请/专利号NZ20000518306

  • 发明设计人 HORROBIN DAVID F;LODER CARI;

    申请日2000-10-12

  • 分类号A61K31/55;A61K31/5375;A61K31/198;A61K31/137;A61P25/00;A61K31/382;A61K31/165;

  • 国家 NZ

  • 入库时间 2022-08-21 23:09:17

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号